Company news
Opthea Limited (ASX:OPT) news
Opthea Limited news releases on 6ix. Latest, Mar 4, 2024: Opthea Corporate Presentation - March 2024
Press releases — page 2
Opthea Corporate Presentation - March 2024
March 4, 2024
Half Yearly Report and Accounts
February 28, 2024
Opthea Reports Half-Year Results and Business Update
February 28, 2024
Opthea Completes Enrollment in First Trial of Sozinibercept
February 14, 2024
Opthea to Receive US$35M Commitment and Additional US$50M
December 26, 2023
Opthea receives A$8.8 million R&D Tax Incentive
December 19, 2023
2023 AGM Chairmans Address
November 29, 2023
Opthea Appoints U.S. Based Leadership
October 26, 2023
Opthea to Participate at the 2023 Euretina Congress
October 2, 2023
Security Class Reinstatement to Quotation OPTOA
September 21, 2023
Opthea Announces Completion of Retail Entitlement Offer
September 20, 2023
Security Class Suspension from Quotation OPTOA
September 14, 2023
Opthea Retail Entitlement Offer Opens
August 30, 2023
Opthea completes institutional offer and increases raise
August 28, 2023
Prospectus
August 24, 2023
Opthea Investor Presentation
August 24, 2023
Opthea announces A$80m Capital raise
August 24, 2023
ASRS 2023 - PK and safety of sozinibercept (OPT-302)
July 31, 2023
Opthea Receives A$8.7million R&D Tax Incentive
March 6, 2023
Half Year Accounts
February 22, 2023
Response to ASX Query
February 16, 2023
Opthea Ph2b Trial Results with OPT-302 published in Journal
February 13, 2023
Opthea Corporate Presentation - San Francisco Jan 2023
January 10, 2023
Chairmans Address to Shareholders
November 15, 2022
Completion of Share Purchase Plan
September 26, 2022
Opthea reports Fiscal Year 2022 Results and Highlights
August 29, 2022
Opthea Appendix 4E and Annual Report 2022
August 29, 2022
Opthea Share Purchase Plan
August 24, 2022
Form 6-K with SEC
August 15, 2022
Opthea Successfully Closes Well Supported US$90m Financing
August 15, 2022
Opthea secures up to US$170m in non-dilutive financing
August 15, 2022
Opthea Data for OPT-302 for PCV presented at ARVO 2022
May 5, 2022
Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting
May 1, 2022
S&P DJI Announces March 2022 Quarterly Rebalance
March 4, 2022
Opthea Half Year Report and Accounts
February 27, 2022
Angiogenesis 2022 -Prof Cheung presentation of PCV data
February 13, 2022
Opthea announces establishment of ATM Equity Program
February 1, 2022
Opthea Receives A$6.6m R&D Tax Incentive
January 24, 2022
Opthea Granted Chinese Patent Covering OPT-302
October 26, 2021
Opthea opens patient enrollment in the Asia-Pacifi Region
October 19, 2021
Opthea Corporate Presentation - October 2021
October 18, 2021
Optheas Phase 3 open for patient recruitment in Europe
October 4, 2021
Opthea reports Fiscal Year 2021 Results and Highlights
August 29, 2021
Optheas OPT-302 Granted Fast-Track for wet AMD
July 5, 2021
Opthea Receives FDA Waiver for Pediatric Study Plan
March 30, 2021
Opthea Treats First Patient in Phase 3 Trials of OPT-302
March 14, 2021
Opthea Finalizes Ph 3 Study Designs and Startup Activities
February 23, 2021
Opthea Receives A$8.5m R&D Tax Incentive
October 26, 2020
Opthea Announces Closing of US Initial Public Offering
October 20, 2020
Opthea Announces Pricing of US Initial Public Offering
October 18, 2020